NATIONAL TAIWAN UNIVERSITY HOSPITAL
- Country
- 🇹🇼Taiwan
- Ownership
- Private
- Established
- 1895-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.ntuh.gov.tw
Clinical Trials
2.4k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1260 trials with phase data)• Click on a phase to view related trials
Modulate Tremor Severity With Low-intensity Focused Ultrasound Stimulation Targeting the Deep Nucleus of Patients With Refractory Hand Tremor.
- Conditions
- Parkinson Disease (PD)Essential TremorDystonic TremorContinuous Theta Burst Stimulation Transcranial Focused Ultrasound
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT07172295
- Locations
- 🇨🇳
National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Hsinchu City, Taiwan
Morphological Changes of Upper Trapezius Muscle After Physotherapy in Oral Cancer
- Conditions
- Oral Cancer
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT07166575
Effectiveness of Pet-Robotic Intervention in Intensive Care Unit Patients
- Conditions
- Spontaneous Breathing Trial in ICUSpontaneous Breathing Trial
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT07163247
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
The Epidemiology Change From 2006 to 2022 of Infective Endocarditis in Taiwan
- Conditions
- Infective Endocarditis
- First Posted Date
- 2025-09-05
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 2247
- Registration Number
- NCT07156292
- Locations
- 🇨🇳
NTUH, Taipei, Taiwan
Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)
- Conditions
- Multiple Myeloma
- Interventions
- Biological: 2-dose PCV13Biological: 1-dose PCV13
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 101
- Registration Number
- NCT07154537
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taipei, Taiwan
- Prev
- 1
- 2
- 3
- 4
- 5
- 489
- Next
News
3D Pathology Technology Reclassifies 67% of HER2-Null Breast Cancer Cases as HER2-Expressing
• JelloX Biotech's 3D pathology technology identified significantly more HER2-low and HER2-ultralow breast tumors compared to conventional diagnostic methods in a study with National Taiwan University Hospital. • Over 50% of analyzed breast cancer cases showed diagnostic discrepancies when re-evaluated with 3D pathology, with 66.7% of initially HER2-null patients reclassified as HER2-expressing. • The improved detection sensitivity could expand treatment eligibility for Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that has shown robust efficacy in HER2-low and HER2-ultralow metastatic breast cancer.
Ainos Advances VELDONA Oral Interferon Platform with Dual Clinical Trial Approvals for Rare Diseases
Ainos has secured TFDA approval for a clinical trial of VELDONA in HIV-related oral warts and IRB clearance for a Sjögren's Syndrome study, targeting two rare diseases with significant unmet needs.
Volition's Nu.Q® Cancer Test Shows Promise in Lung Cancer Screening and Pan-Cancer Detection
Volition has enrolled the first patient in a 500-patient validation study at National Taiwan University Hospital to evaluate Nu.Q® Cancer technology for distinguishing between malignant and benign pulmonary nodules in LDCT lung cancer screening.
Novel Small-Molecule Drug Shows Promise in Treating Inflammatory Bowel Disease
Taiwanese researchers from NTHU and NHRI have developed a breakthrough small-molecule drug that treats chronic intestinal inflammation by blocking PANX1 ion channels in intestinal cells.